Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer

Tsuyoshi Hata, Yukako Mokutani, Hidekazu Takahashi, Akira Inoue, Koji Munakata, Kazuya Nagata, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Chu Matsuda, Kohei Murata, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori, Hirofumi Yamamoto

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)


Recent studies have shown that microRNAs (miRNAs) are involved in the progression of colorectal cancer (CRC). The aim of this study is to identify a novel miRNA that especially relates to liver metastasis and to explore the underlying mechanism. Differentially expressed miRNAs were analyzed using microarray, in primary CRC tumors without metastasis (n=16), those with liver metastasis (n=12), and liver metastatic lesions (n=8). We found that MIR-487b level decreased in liver metastatic lesions, and qRT-PCR confirmed the results in the validating cohort (n=134). Survival analysis indicated that high expression of MIR-487b was associated with better prognosis. In vitro studies were also performed to investigate the functional significance of MIR-487b in human CRC cell lines. MIR-487b showed an inhibitory effect on cell proliferation and invasion of CRC cells. MIR-487b downregulated KRAS and inhibited its downstream signal pathways, and the luciferase reporter assay revealed that MIR-487b directly targeted LRP6, a receptor for WNT/β-catenin signaling. These findings showed that decrease in MIR-487b was related with liver metastasis. Our data suggest a possibility that MIR-487b may suppress metastasis of CRC progression through inhibition of KRAS.

Original languageEnglish
Pages (from-to)487-496
Number of pages10
JournalInternational journal of oncology
Issue number2
Publication statusPublished - Feb 2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer'. Together they form a unique fingerprint.

Cite this